Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Rating) was the target of a significant drop in short-term interest during the month of April. As of April 15, there was short interest totaling 3,900 shares, down 76.8% from the March 31 total of 16,800 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average trading volume of 66,100 shares, the short-term interest rate ratio is currently 0.1 day.
Several equity analysts weighed in on CMMB shares. Oppenheimer lowered his price target on Chemomab Therapeutics from $30.00 to $20.00 and set an “outperform” rating for the company in a Thursday, March 10 research report. Zacks Investment Research downgraded shares of Chemomab Therapeutics from a “hold” rating to a “strong sell” rating in a Monday, March 14 report.
Separately, director Neil Harris Cohen purchased 6,000 shares of the company in a transaction dated Monday, March 14. The shares were acquired at an average price of $4.35 per share, for a total transaction of $26,100.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available via this hyperlink. Insiders purchased a total of 10,750 shares of the company worth $45,440 over the past ninety days. Company insiders own 12.22% of the company’s shares.
Several hedge funds have recently increased or reduced their holdings in CMMB. Yahav Achim Ve Achayot Provident Funds Management Co Ltd. acquired a new position in Chemomab Therapeutics stock in Q3 worth approximately $34,000. GSA Capital Partners LLP acquired a new position in Chemomab Therapeutics in Q4 worth approximately $78,000. Geode Capital Management LLC acquired a new stake in Chemomab Therapeutics in Q3 valued at approximately $152,000. Virtu Financial LLC acquired a new position in Chemomab Therapeutics during the fourth quarter worth approximately $155,000. Finally, Advisor Group Holdings Inc. acquired a new position in Chemomab Therapeutics in Q3 valued at approximately $608,000. Institutional investors hold 28.75% of the company’s shares.
Shares of Chemomab Therapeutics opened at $3.14 on Thursday. Chemomab Therapeutics has a 1 year minimum of $3.04 and a 1 year maximum of $35.99. The company’s 50-day moving average is $4.19 and its 200-day moving average is $6.41. The company has a market capitalization of $35.81 million, a P/E ratio of -2.66 and a beta of 0.99.
Chemomab Therapeutics (NASDAQ:CMMB – Get Rating) last released quarterly earnings data on Wednesday, March 9. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($0.40) by ($0.04). As a group, stock analysts expect Chemomab Therapeutics to post year-to-date EPS of -1.94.
About Chemomab Therapeutics (Get a rating)
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The Company’s lead clinical product candidate is CM-101, a humanized monoclonal antibody that impairs the basic function of the soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
Get news and reviews for Chemomab Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Chemomab Therapeutics and related companies with MarketBeat.com’s free daily email newsletter.